Stocktoria
Jazz Pharmaceuticals plc JAZZ
Jazz Pharmaceuticals plc (JAZZ) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $4.3B at a -8.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-11 | Morgan Stanley | Overweight (main) |
| 2026-08-04 | JP Morgan | Overweight (main) |
| 2026-08-04 | Truist Securities | Buy (main) |
| 2026-08-04 | TD Cowen | Buy (main) |
| 2026-08-04 | Wells Fargo | Overweight (main) |
| 2026-08-04 | Morgan Stanley | Overweight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.165 |
| Retained earnings / assets | 0.055 |
| EBIT / assets | -0.037 |
| Equity / liabilities | 0.588 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc | 5/9 | 1.63 | — | +4.9% |
| PRGO | PERRIGO Co plc | 4/9 | -0.37 | — | -2.8% |
| ELAN | Elanco Animal Health Inc | 6/9 | — | — | +6.2% |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | 5/9 | -0.11 | 124 | +65.2% |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 4/9 | 7.43 | 32.7 | +12.9% |
| ONC | BeOne Medicines Ltd. | 7/9 | 1.78 | — | +40.2% |
| UTHR | UNITED THERAPEUTICS Corp | 7/9 | 16.93 | 17.4 | +10.6% |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
FAQ
Is JAZZ financially healthy?
Jazz Pharmaceuticals plc's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does JAZZ pay a dividend?
No, Jazz Pharmaceuticals plc does not currently pay a dividend.
How profitable is JAZZ?
In FY2025, Jazz Pharmaceuticals plc had a net margin of -8.3% and a return on equity of -8.2%.
Is JAZZ overvalued or undervalued?
Jazz Pharmaceuticals plc trades at about 28.8× trailing earnings — above its 10-year norm (10-year range 14.4×–182.1×, median 20.1×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for JAZZ?
The average Wall-Street price target for Jazz Pharmaceuticals plc is $281.10, about 12.9% above the recent price, from 20 analysts (consensus: buy).
Is JAZZ a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Jazz Pharmaceuticals plc: a Piotroski F-score of 5/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.